Ernexa Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $5.56 million. The enterprise value is $4.17 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 29.15 million shares outstanding. The number of shares has increased by 593.08% in one year.
| Current Share Class | 29.15M |
| Shares Outstanding | 29.15M |
| Shares Change (YoY) | +593.08% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 29.86% |
| Owned by Institutions (%) | 4.54% |
| Float | 20.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/TBV Ratio | 15.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.01 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -345.15 |
Financial Efficiency
Return on equity (ROE) is -686.69% and return on invested capital (ROIC) is -220.79%.
| Return on Equity (ROE) | -686.69% |
| Return on Assets (ROA) | -104.92% |
| Return on Invested Capital (ROIC) | -220.79% |
| Return on Capital Employed (ROCE) | -342.48% |
| Weighted Average Cost of Capital (WACC) | 38.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.01M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -45,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.11% in the last 52 weeks. The beta is 6.85, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 6.85 |
| 52-Week Price Change | -94.11% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 36.33 |
| Average Volume (20 Days) | 634,745 |
Short Selling Information
The latest short interest is 201,143, so 0.69% of the outstanding shares have been sold short.
| Short Interest | 201,143 |
| Short Previous Month | 160,378 |
| Short % of Shares Out | 0.69% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.32M |
| Pretax Income | -14.13M |
| Net Income | -14.10M |
| EBITDA | -9.25M |
| EBIT | -9.32M |
| Earnings Per Share (EPS) | -$2.24 |
Full Income StatementBalance Sheet
The company has $1.88 million in cash and $490,000 in debt, giving a net cash position of $1.39 million or $0.05 per share.
| Cash & Cash Equivalents | 1.88M |
| Total Debt | 490,000 |
| Net Cash | 1.39M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 2.40M |
| Book Value Per Share | 0.31 |
| Working Capital | 20,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.02 million and capital expenditures -$37,000, giving a free cash flow of -$7.05 million.
| Operating Cash Flow | -7.02M |
| Capital Expenditures | -37,000 |
| Depreciation & Amortization | 65,000 |
| Net Borrowing | 2.25M |
| Free Cash Flow | -7.05M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |